Circular Genomics and Vitazi.ai Partner to Advance Multimodal Early Detection of Alzheimer’s Disease

Analytical Framework Combines AI-Powered Retinal Imaging with Proprietary Circular RNA Biomarkers to Unlock Scalable, Non-Invasive Pathway for Early-Stag...

May 01, 2026 | Friday | News
AIDS Healthcare Foundation Presses Shareholders to Challenge Gilead Sciences Patent Strategy at 2026 AGM with Proposal 6

With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...

April 29, 2026 | Wednesday | News
PacBio and Covaris Unveil Integrated Workflow to Unlock HiFi Sequencing from FFPE Tumor Samples

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...

April 17, 2026 | Friday | News
Aligos Therapeutics Secures FDA Fast Track for Pevifoscorvir Sodium as Phase 2 HBV Study Advances

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection HBeAg- cohort sample size increa...

April 16, 2026 | Thursday | News
Cepheid And Oxford Nanopore Expand Collaboration To Advance Rapid Pathogen Genomic Workflows

Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...

April 16, 2026 | Thursday | News
SonoNeu Emerges from Stealth to Advance Sonogenetics as a Breakthrough Drug-Free Therapeutic Modality

Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged&r...

April 08, 2026 | Wednesday | News
Cocrystal Pharma, Inc. Secures FDA Fast Track for CDI-988, Advancing First Oral Antiviral for Norovirus

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob...

April 07, 2026 | Tuesday | News
FDA Extends EYLEA HD Dosing Interval to 20 Weeks, Advancing Long-Term Retinal Care

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...

April 07, 2026 | Tuesday | News
ORIC Advances Rinzimetostat To Phase 3 With Strong Efficacy And Safety In Prostate Cancer

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...

April 02, 2026 | Thursday | News
Biogen to Acquire Apellis in $5.6B Deal to Strengthen Immunology and Rare Disease Portfolio

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...

April 01, 2026 | Wednesday | News
FDA Grants Fast Track Designation to Quoin’s QRX003 Lotion for Netherton Syndrome

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet ...

March 13, 2026 | Friday | News
GenSight Biologics Advances Early Access Programs for LUMEVOQ Gene Therapy in Rare Vision Disorder

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...

March 10, 2026 | Tuesday | News
ImmunoScape Advances Seed And Boost Cancer Therapy Programme With United States Clinical Collaboration

The company also announced a strategic investment from Leonardo DiCaprio ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures an...

March 06, 2026 | Friday | News
Cure Rare Disease and LGMD2L Foundation Launch $7.65M Partnership to Advance ANO5 Gene Therapy

  Cure Rare Disease (CRD), a non-profit biotechnology organization, announced a landmark partnership with the LGMD2L Foundation. This collaboration i...

March 04, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close